mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

	Gene Summary
	Ligand Binding Site Mutation Information
	Protein Structure Related Information
	Gene Expression and Gene-Gene Network
	Phenotype Information
	Pharmacological Information
	Conservation Information for LBS

Gene summary for VHL

Gene summary

Basic gene Info.	Gene symbol	VHL
	Gene name	von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase
	Synonyms	HRCA1\|RCA1\|VHL1\|pVHL
	Cytomap	UCSC genome browser: 3p25.3
	Type of gene	protein-coding
	RefGenes	NM_000551.3, NM_198156.2,
	Description	elongin binding proteinprotein G7von Hippel-Lindau disease tumor suppressor
	Modification date	20141219
dbXrefs	MIM : 608537
	HGNC : HGNC
	HPRD : 01905
Protein	UniProt: P40337 go to UniProt's Cross Reference DB Table
Expression	CleanEX: HS_VHL
	BioGPS: 7428
Pathway	NCI Pathway Interaction Database: VHL
	KEGG: VHL
	REACTOME: VHL
	Pathway Commons: VHL
Context	iHOP: VHL
	ligand binding site mutation search in PubMed: VHL
	UCL Cancer Institute: VHL
Assigned class in mutLBSgeneDB	C: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez

GO ID	GO Term	PubMed ID
GO:0016567	protein ubiquitination	24899725
GO:0061428	negative regulation of transcription from RNA polymerase II promoter in response to hypoxia	11641274

Top

Ligand binding site mutations for VHL

Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)

: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency

LBS	AAchange of nsSNV	Cancer type	# samples
L118	F119L	COAD	6
L89	L89H	KIRC	6
S111	S111N	KIRC	4
H115	H115N	KIRC	3
I75,Q73	V74D	KIRC	3
Q203	E204G	COAD	2
R107	R107P	KIRC	2
W88	W88L	KIRC	2
S111	S111R	KIRC	2
R113,H115	G114R	KIRC	2
N67	S65L	KIRC	2
N78	N78D	KIRC	2
L89	L89P	KIRC	2
I75,Q73	V74F	COAD	1
L116	L116I	COAD	1
L201	R200L	COAD	1
L116	L116P	COAD	1
R113,H115	G114D	COAD	1
T105	T105S	KIRC	1
R113,H115	G114A	KIRC	1
I109	I109N	KIRC	1
N67	S65W	KIRC	1
L118	L118P	KIRC	1
Q96	P95Q	KIRC	1
H110	H110P	KIRC	1
I75,Q73	V74G	KIRC	1
R79	R79P	KIRC	1
W88	W88R	KIRC	1
R107	R107G	KIRC	1
N78	N78S	KIRC	1
Y112	Y112D	KIRC	1
P86	P86L	KIRC	1
D92	G93V	KIRC	1
N78	N78Y	KIRC	1
H115	H115Y	KIRC	1
R79	S80I	KIRC	1
W117	W117C	KIRC	1
L118	R120G	KIRC	1
R79	S80R	KIRC	1
L89,F91	N90I	KIRC	1
R79	R79G	LUSC	1
Q203	R205C	UCEC	1

cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Clinical information for VHL from My Cancer Genome.

Von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase (VHL) is a gene that encodes a member of a protein complex with ubiquitin ligase activity. The protein functions in ubiquitination and degradation of a transcription factor that regulates gene expression. Missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions and insertions are observed in cancers such as intestinal cancer, kidney cancer, and cancer of the paratesticular tissues.Modified: July 1, 2015

Top

Protein structure related information for VHL

Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
(ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)

: nsSNV at non-LBS

: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.

LBS	AAchange of nsSNV	Relative stability change
Q73	V74G	-1.6857773
I75	V74G	-1.6857773
L89	L89H	-1.6618255
I109	I109N	-1.5521516
Q73	V74D	-1.4552574
I75	V74D	-1.4552574
L89	L89P	-1.418946
L118	L118P	-1.41588
L118	R120G	-1.2530224
Q73	V74F	-1.2114338
I75	V74F	-1.2114338
Q203	E204G	-1.1995149
W117	W117C	-1.1666553
R107	R107G	-1.1104697
W88	W88R	-1.0169899
Q203	R205C	-0.91973133
R79	R79G	-0.87112339
Y112	Y112D	-0.85978031
H115	H115N	-0.85925923
N67	S65W	-0.82207827
T105	T105S	-0.80474764
S111	S111N	-0.80463841
L201	R200L	-0.76145402
R79	S80R	-0.75274746
R107	R107P	-0.72244546
W88	W88L	-0.69630643
R79	S80I	-0.59801424
Q96	P95Q	-0.58807486
R113	G114A	-0.55187001
H115	G114A	-0.55187001
R79	R79P	-0.55163338
N67	S65L	-0.50124247
H115	H115Y	-0.4977395
L118	F119L	-0.49436971
P86	P86L	-0.49291838
H115	G114D	-0.47759398
R113	G114D	-0.47759398
N78	N78D	-0.45778062
H110	H110P	-0.41663098
S111	S111R	-0.38179869
F91	N90I	-0.34825121
L89	N90I	-0.34825121
L116	L116P	-0.34608739
N78	N78S	-0.29011547
D92	G93V	-0.22932356
R113	G114R	-0.19945525
H115	G114R	-0.19945525
N78	N78Y	-0.091569572
L116	L116I	-0.091540309

(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for VHL from PDB

PDB ID	PDB title	PDB structure
1VCB	THE VHL-ELONGINC-ELONGINB STRUCTURE

Top

Differential gene expression and gene-gene network for VHL

Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

VHL_COAD_DE

VHL_KIRC_DE

Differential co-expressed gene network based on protein-protein interaction data (CePIN)

* Left PPI network was created from samples with mutations in the LBS of VHL and the right PPI network was created from samples without mutations in the LBS of VHL. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.

* In COAD

* In KIRC

Top

Phenotype information for VHL

Gene level disease information (DisGeNet)

Disease ID	Disease name	# PubMed	Association type
umls:C0007134	Carcinoma, Renal Cell	207	AlteredExpression, Biomarker, GeneticVariation
umls:C0019562	von Hippel-Lindau Disease	188	AlteredExpression, Biomarker, GeneticVariation
umls:C0031511	Pheochromocytoma	81	Biomarker, GeneticVariation
umls:C0007097	Carcinoma	30	AlteredExpression, Biomarker, GeneticVariation
umls:C0022665	Kidney Neoplasms	22	AlteredExpression, Biomarker, GeneticVariation
umls:C0027672	Neoplastic Syndromes, Hereditary	8	Biomarker, GeneticVariation
umls:C0001430	Adenoma	5	Biomarker
umls:C0024121	Lung Neoplasms	2	Biomarker
umls:C0027708	Wilms Tumor	1	Biomarker

Mutation level pathogenic information (ClinVar annotation)

Allele ID	AA change	Clinical significance	Origin	Phenotype IDs
45561	R107P	Likely pathogenic	Germline	GeneReviews:NBK1463 MedGen:C0019562 OMIM:193300 Orphanet:ORPHA892 SNOMED CT:46659004
52766	S65W	Pathogenic	Germline	GeneReviews:NBK1463 MedGen:C0019562 OMIM:193300 Orphanet:ORPHA892 SNOMED CT:46659004
52768	R107G	Pathogenic	Germline	GeneReviews:NBK1463 MedGen:C0019562 OMIM:193300 Orphanet:ORPHA892 SNOMED CT:46659004
99233	N78S	Pathogenic	Germline	GeneReviews:NBK1463 MedGen:C0019562 OMIM:193300 Orphanet:ORPHA892 SNOMED CT:46659004
99235	I109N	Likely pathogenic	Germline	GeneReviews:NBK1463 MedGen:C0019562 OMIM:193300 Orphanet:ORPHA892 SNOMED CT:46659004
178148	W117C	Pathogenic	Germline	GeneReviews:NBK1463 MedGen:C0019562 OMIM:193300 Orphanet:ORPHA892 SNOMED CT:46659004
180112	S65L	Pathogenic	Germline	GeneReviews:NBK1463 MedGen:C0019562 OMIM:193300 Orphanet:ORPHA892 SNOMED CT:46659004 MedGen:C0027672 SNOMED CT:699346009
180115	P86L	Pathogenic	Germline	MedGen:C0027672 SNOMED CT:699346009
180117	L89P	Pathogenic	Germline	MedGen:C0027672 SNOMED CT:699346009

Top

Pharmacological information for VHL

Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Drug information targeting mutLBSgene (Approved drugs only)

Drug status

DrugBank ID

Name

Type

Drug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of VHL go to BioLip

Ligand ID	Ligand short name	Ligand long name	PDB ID	PDB name	mutLBS
ARG		ARGININE	4bkt	I	L201 Q203
III		Peptide ligand (MET,LEU,ALA,PRO,TYR,ILE,PRO,MET,ASP,ASP,ASP,PHE,GLN,LEU,ARG)	1lm8	V	N67 I75 N78 R79 W88 F91 T105 R107 I109 H110 S111 Y112 H115 W117
III		Peptide ligand (GLU,MET,LEU,ALA,PRO,TYR,ILE,PRO,MET,ASP,ASP,ASP,PHE,GLN,LEU,ARG,SER,PHE)	1lqb	C	N67 I75 N78 R79 W88 F91 T105 R107 I109 H110 S111 Y112 H115 W117
III		Peptide ligand (GLU,ALA,LEU,ALA,PRO,TYR,ILE,PRO,MET,ASP,ASP,ASP,PHE,GLN,LEU)	4ajy	V	N67 I75 N78 W88 F91 T105 R107 H110 S111 Y112 H115 W117
3JH		N-ACETYL-L-LEUCYL-3-METHYL-L-VALYL-(4R)-4-HYDROXY-N-[4- (4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9j	F	N67 P86 W88 F91 I109 H110 S111 Y112 H115 W117
3JO		N-ACETYL-L-PHENYLALANYL-3-METHYL-L-VALYL-(4R)-4- HYDROXY-N-[4-(4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L- PROLINAMIDE	4w9k	F	N67 P86 W88 F91 I109 H110 S111 Y112 H115 W117
3JJ		N-ACETYL-3-METHYL-L-VALYL-3-METHYL-L-VALYL-(4R)-4- HYDROXY-N-[4-(4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L- PROLINAMIDE	4w9l	F	N67 P86 W88 F91 I109 H110 S111 Y112 H115 W117
3JH		N-ACETYL-L-LEUCYL-3-METHYL-L-VALYL-(4R)-4-HYDROXY-N-[4- (4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9j	I	N67 P86 W88 F91 R107 I109 H110 S111 Y112 H115 W117
3JH		N-ACETYL-L-LEUCYL-3-METHYL-L-VALYL-(4R)-4-HYDROXY-N-[4- (4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9j	L	N67 P86 W88 F91 R107 I109 H110 S111 Y112 H115 W117
3JJ		N-ACETYL-3-METHYL-L-VALYL-3-METHYL-L-VALYL-(4R)-4- HYDROXY-N-[4-(4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L- PROLINAMIDE	4w9l	I	N67 P86 W88 F91 R107 I109 H110 S111 Y112 H115 W117
3JH		N-ACETYL-L-LEUCYL-3-METHYL-L-VALYL-(4R)-4-HYDROXY-N-[4- (4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9j	C	N67 W88 F91 I109 H110 S111 Y112 H115 W117
3JJ		N-ACETYL-3-METHYL-L-VALYL-3-METHYL-L-VALYL-(4R)-4- HYDROXY-N-[4-(4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L- PROLINAMIDE	4w9l	C	N67 W88 F91 I109 H110 S111 Y112 H115 W117
3JJ		N-ACETYL-3-METHYL-L-VALYL-3-METHYL-L-VALYL-(4R)-4- HYDROXY-N-[4-(4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L- PROLINAMIDE	4w9l	L	N67 W88 F91 R107 I109 H110 S111 Y112 H115 W117
ZTD		METHYL 4-[({(4R)-4-HYDROXY-1-[(3- METHYLISOXAZOL-5-YL)ACETYL]-L-PROLYL}AMINO)METHYL] BENZOATE	3ztd	I	P86 W88 F91 I109 H110 S111 Y112 H115 W117
L8B		(4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5-YL)ACETYL]-N-[4-(1,3-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	3zrc	L	P86 W88 F91 R107 I109 H110 S111 Y112 H115 W117
ZTD		METHYL 4-[({(4R)-4-HYDROXY-1-[(3- METHYLISOXAZOL-5-YL)ACETYL]-L-PROLYL}AMINO)METHYL] BENZOATE	3ztd	L	P86 W88 F91 R107 I109 H110 S111 Y112 H115 W117
UCK		(2S,4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[(4- CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4b95	I	P86 W88 F91 R107 I109 H110 S111 Y112 H115 W117
3JF		N-ACETYL-3-METHYL-L-VALYL-(4R)-4-HYDROXY-N-[4-(4- METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9h	I	P86 W88 F91 R107 I109 H110 S111 Y112 H115 W117
3JF		N-ACETYL-3-METHYL-L-VALYL-(4R)-4-HYDROXY-N-[4-(4- METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9h	L	P86 W88 F91 R107 I109 H110 S111 Y112 H115 W117
3JO		N-ACETYL-L-PHENYLALANYL-3-METHYL-L-VALYL-(4R)-4- HYDROXY-N-[4-(4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L- PROLINAMIDE	4w9k	I	P86 W88 F91 R107 I109 H110 S111 Y112 H115 W117
3JU		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(4-METHYL- 1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9f	I	P86 W88 R107 I109 H110 S111 Y112 H115 W117
3JU		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(4-METHYL- 1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9f	L	P86 W88 R107 I109 H110 S111 Y112 H115 W117
3JS		(4R)-1-ACETYL-4-HYDROXY-L-PROLYL-(4R)-4-HYDROXY-N-[4- (4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9i	I	P86 W88 R107 I109 H110 S111 Y112 H115 W117
GLU		L-GLUTAMIC ACID	4bkt	F	Q203
TG0		(2S,4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE	4b9k	C	R107
TG0		(2S,4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE	4b9k	F	R107
TG0		(2S,4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE	4b9k	I	R107
TG0		(2S,4R)-1-(3-AMINO-2-METHYLBENZOYL)-4- HYDROXY-N-(4-(4-METHYLTHIAZOL-5-YL)BENZYL) PYRROLIDINE-2-CARBOXAMIDE	4b9k	L	R107
QD0		(2S,4R)-N-METHYL-1-[2-(3-METHYL-1,2-OXAZOL-5- YL)ETHANOYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4bkt	C	W88 F91 H110 S111 Y112 H115 W117
QD0		(2S,4R)-N-METHYL-1-[2-(3-METHYL-1,2-OXAZOL-5- YL)ETHANOYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4bkt	F	W88 F91 H110 S111 Y112 H115 W117
QD0		(2S,4R)-N-METHYL-1-[2-(3-METHYL-1,2-OXAZOL-5- YL)ETHANOYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4bkt	I	W88 F91 H110 S111 Y112 H115 W117
QD0		(2S,4R)-N-METHYL-1-[2-(3-METHYL-1,2-OXAZOL-5- YL)ETHANOYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4bkt	L	W88 F91 H110 S111 Y112 H115 W117
TR0		(4R)-N-(BIPHENYL-4-YLMETHYL)-4-HYDROXY-1-[(3- METHYLISOXAZOL-5-YL)ACETYL]-L-PROLINAMIDE	3ztc	I	W88 F91 I109 H110 S111 Y112 H115 W117
TR0		(4R)-N-(BIPHENYL-4-YLMETHYL)-4-HYDROXY-1-[(3- METHYLISOXAZOL-5-YL)ACETYL]-L-PROLINAMIDE	3ztc	L	W88 F91 I109 H110 S111 Y112 H115 W117
3JF		N-ACETYL-3-METHYL-L-VALYL-(4R)-4-HYDROXY-N-[4-(4- METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9h	C	W88 F91 I109 H110 S111 Y112 H115 W117
3JF		N-ACETYL-3-METHYL-L-VALYL-(4R)-4-HYDROXY-N-[4-(4- METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9h	F	W88 F91 I109 H110 S111 Y112 H115 W117
3JO		N-ACETYL-L-PHENYLALANYL-3-METHYL-L-VALYL-(4R)-4- HYDROXY-N-[4-(4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L- PROLINAMIDE	4w9k	C	W88 F91 I109 H110 S111 Y112 H115 W117
UCK		(2S,4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[(4- CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4b95	L	W88 F91 Q96 I109 H110 S111 Y112 H115 W117
UCK		(2S,4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[(4- CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4b95	C	W88 F91 Q96 R107 I109 H110 S111 Y112 H115 W117
ZTD		METHYL 4-[({(4R)-4-HYDROXY-1-[(3- METHYLISOXAZOL-5-YL)ACETYL]-L-PROLYL}AMINO)METHYL] BENZOATE	3ztd	F	W88 F91 R107 H110 S111 Y112 H115 W117
L8B		(4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5-YL)ACETYL]-N-[4-(1,3-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	3zrc	I	W88 F91 R107 I109 H110 S111 Y112 H115
L8B		(4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5-YL)ACETYL]-N-[4-(1,3-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	3zrc	C	W88 F91 R107 I109 H110 S111 Y112 H115 W117
TR0		(4R)-N-(BIPHENYL-4-YLMETHYL)-4-HYDROXY-1-[(3- METHYLISOXAZOL-5-YL)ACETYL]-L-PROLINAMIDE	3ztc	F	W88 F91 R107 I109 H110 S111 Y112 H115 W117
ZUN		(4R)-N-[4-(DIHYDROXYAMINO)BENZYL]-4-HYDROXY- 1-[(3-METHYLISOXAZOL-5-YL)ACETYL]-L- PROLINAMIDE	3zun	C	W88 F91 R107 I109 H110 S111 Y112 H115 W117
ZUN		(4R)-N-[4-(DIHYDROXYAMINO)BENZYL]-4-HYDROXY- 1-[(3-METHYLISOXAZOL-5-YL)ACETYL]-L- PROLINAMIDE	3zun	F	W88 F91 R107 I109 H110 S111 Y112 H115 W117
ZUN		(4R)-N-[4-(DIHYDROXYAMINO)BENZYL]-4-HYDROXY- 1-[(3-METHYLISOXAZOL-5-YL)ACETYL]-L- PROLINAMIDE	3zun	I	W88 F91 R107 I109 H110 S111 Y112 H115 W117
ZUN		(4R)-N-[4-(DIHYDROXYAMINO)BENZYL]-4-HYDROXY- 1-[(3-METHYLISOXAZOL-5-YL)ACETYL]-L- PROLINAMIDE	3zun	L	W88 F91 R107 I109 H110 S111 Y112 H115 W117
UCK		(2S,4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[(4- CHLOROPHENYL)METHYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4b95	F	W88 F91 R107 I109 H110 S111 Y112 H115 W117
3JO		N-ACETYL-L-PHENYLALANYL-3-METHYL-L-VALYL-(4R)-4- HYDROXY-N-[4-(4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L- PROLINAMIDE	4w9k	L	W88 F91 R107 I109 H110 S111 Y112 H115 W117
V6F		(4R)-1-ACETYL-4-HYDROXY-N-METHYL-L-PROLINAMIDE	4awj	C	W88 H110 S111 Y112 H115 W117
V6F		(4R)-1-ACETYL-4-HYDROXY-N-METHYL-L-PROLINAMIDE	4awj	F	W88 H110 S111 Y112 H115 W117
V6F		(4R)-1-ACETYL-4-HYDROXY-N-METHYL-L-PROLINAMIDE	4awj	I	W88 H110 S111 Y112 H115 W117
V6F		(4R)-1-ACETYL-4-HYDROXY-N-METHYL-L-PROLINAMIDE	4awj	L	W88 H110 S111 Y112 H115 W117
L8B		(4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5-YL)ACETYL]-N-[4-(1,3-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	3zrc	F	W88 I109 H110 S111 Y112 H115 W117
TR0		(4R)-N-(BIPHENYL-4-YLMETHYL)-4-HYDROXY-1-[(3- METHYLISOXAZOL-5-YL)ACETYL]-L-PROLINAMIDE	3ztc	C	W88 I109 H110 S111 Y112 H115 W117
X6C		(2S,4R)-1-ETHANOYL-N-[[4-(1,3-OXAZOL-5-YL) PHENYL]METHYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4bks	C	W88 I109 H110 S111 Y112 H115 W117
3JK		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(4-METHYL- 1,3-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9d	C	W88 I109 H110 S111 Y112 H115 W117
3JK		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(4-METHYL- 1,3-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9d	F	W88 I109 H110 S111 Y112 H115 W117
3JU		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(4-METHYL- 1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9f	C	W88 I109 H110 S111 Y112 H115 W117
3JU		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(4-METHYL- 1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9f	F	W88 I109 H110 S111 Y112 H115 W117
3JS		(4R)-1-ACETYL-4-HYDROXY-L-PROLYL-(4R)-4-HYDROXY-N-[4- (4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9i	C	W88 I109 H110 S111 Y112 H115 W117
3JS		(4R)-1-ACETYL-4-HYDROXY-L-PROLYL-(4R)-4-HYDROXY-N-[4- (4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9i	F	W88 I109 H110 S111 Y112 H115 W117
ZTD		METHYL 4-[({(4R)-4-HYDROXY-1-[(3- METHYLISOXAZOL-5-YL)ACETYL]-L-PROLYL}AMINO)METHYL] BENZOATE	3ztd	C	W88 R107 I109 H110 S111 Y112 H115 W117
X6C		(2S,4R)-1-ETHANOYL-N-[[4-(1,3-OXAZOL-5-YL) PHENYL]METHYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4bks	F	W88 R107 I109 H110 S111 Y112 H115 W117
X6C		(2S,4R)-1-ETHANOYL-N-[[4-(1,3-OXAZOL-5-YL) PHENYL]METHYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4bks	I	W88 R107 I109 H110 S111 Y112 H115 W117
X6C		(2S,4R)-1-ETHANOYL-N-[[4-(1,3-OXAZOL-5-YL) PHENYL]METHYL]-4-OXIDANYL-PYRROLIDINE-2- CARBOXAMIDE	4bks	L	W88 R107 I109 H110 S111 Y112 H115 W117
3JG		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(1,3- OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9c	C	W88 R107 I109 H110 S111 Y112 H115 W117
3JG		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(1,3- OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9c	F	W88 R107 I109 H110 S111 Y112 H115 W117
3JG		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(1,3- OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9c	I	W88 R107 I109 H110 S111 Y112 H115 W117
3JG		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(1,3- OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9c	L	W88 R107 I109 H110 S111 Y112 H115 W117
3JK		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(4-METHYL- 1,3-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9d	I	W88 R107 I109 H110 S111 Y112 H115 W117
3JK		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(4-METHYL- 1,3-OXAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9d	L	W88 R107 I109 H110 S111 Y112 H115 W117
3JT		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(1,3- THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9e	C	W88 R107 I109 H110 S111 Y112 H115 W117
3JT		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(1,3- THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9e	F	W88 R107 I109 H110 S111 Y112 H115 W117
3JT		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(1,3- THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9e	I	W88 R107 I109 H110 S111 Y112 H115 W117
3JT		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[4-(1,3- THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9e	L	W88 R107 I109 H110 S111 Y112 H115 W117
3JV		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[3-METHYL-4- (1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9g	C	W88 R107 I109 H110 S111 Y112 H115 W117
3JV		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[3-METHYL-4- (1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9g	F	W88 R107 I109 H110 S111 Y112 H115 W117
3JV		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[3-METHYL-4- (1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9g	I	W88 R107 I109 H110 S111 Y112 H115 W117
3JV		(4R)-1-(3,3-DIMETHYLBUTANOYL)-4-HYDROXY-N-[3-METHYL-4- (1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9g	L	W88 R107 I109 H110 S111 Y112 H115 W117
3JS		(4R)-1-ACETYL-4-HYDROXY-L-PROLYL-(4R)-4-HYDROXY-N-[4- (4-METHYL-1,3-THIAZOL-5-YL)BENZYL]-L-PROLINAMIDE	4w9i	L	W88 R107 I109 H110 S111 Y112 H115 W117

Top

Conservation information for LBS of VHL

Multiple alignments for P40337 in multiple species

LBS	AA sequence	# species	Species
D92	VWLNFDGEPQP	2	Homo sapiens, Canis lupus familiaris
D92	LWLNFDGEPQP	2	Mus musculus, Rattus norvegicus
E6	MPRKAASPEEA	2	Mus musculus, Rattus norvegicus
E6	MPRRAENWDEA	1	Homo sapiens
E6	MPRKAGSVEEA	1	Canis lupus familiaris
F76	PSQVIFCNRSP	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
F91	PVWLNFDGEPQ	2	Homo sapiens, Canis lupus familiaris
F91	PLWLNFDGEPQ	2	Mus musculus, Rattus norvegicus
G104	PTLPPGTGRRI	3	Homo sapiens, Rattus norvegicus, Canis lupus familiaris
G104	PILPPGTGRRI	1	Mus musculus
G106	LPPGTGRRIHS	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
H110	TGRRIHSYRGH	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
H115	HSYRGHLWLFR	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
I109	GTGRRIHSYRG	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
I75	EPSQVIFCNRS	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
L101	QPYPTLPPGTG	3	Homo sapiens, Rattus norvegicus, Canis lupus familiaris
L101	QPYPILPPGTG	1	Mus musculus
L116	SYRGHLWLFRD	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
L118	RGHLWLFRDAG	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
L201	KDLERLTQERI	1	Homo sapiens
L201	KDIQRLSQEHL	1	Mus musculus
L201	KDIQRLTQEHL	1	Rattus norvegicus
L201	KDLERLAQEHI	1	Canis lupus familiaris
L89	VLPVWLNFDGE	2	Homo sapiens, Canis lupus familiaris
L89	VLPLWLNFDGE	2	Mus musculus, Rattus norvegicus
N67	VLRSVNSREPS	3	Homo sapiens, Mus musculus, Rattus norvegicus
N67	VLRSVNSCEPS	1	Canis lupus familiaris
N78	QVIFCNRSPRV	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
P86	PRVVLPVWLNF	2	Homo sapiens, Canis lupus familiaris
P86	PRVVLPLWLNF	2	Mus musculus, Rattus norvegicus
P99	EPQPYPTLPPG	3	Homo sapiens, Rattus norvegicus, Canis lupus familiaris
P99	EPQPYPILPPG	1	Mus musculus
Q203	LERLTQERIAH	1	Homo sapiens
Q203	IQRLSQEHLES	1	Mus musculus
Q203	IQRLTQEHLEN	1	Rattus norvegicus
Q203	LERLAQEHIEN	1	Canis lupus familiaris
Q73	SREPSQVIFCN	3	Homo sapiens, Mus musculus, Rattus norvegicus
Q73	SCEPSQVIFCN	1	Canis lupus familiaris
Q96	FDGEPQPYPTL	3	Homo sapiens, Rattus norvegicus, Canis lupus familiaris
Q96	FDGEPQPYPIL	1	Mus musculus
R107	PPGTGRRIHSY	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
R108	PGTGRRIHSYR	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
R113	RIHSYRGHLWL	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
R69	RSVNSREPSQV	3	Homo sapiens, Mus musculus, Rattus norvegicus
R69	RSVNSCEPSQV	1	Canis lupus familiaris
R79	VIFCNRSPRVV	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
S111	GRRIHSYRGHL	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
T100	PQPYPTLPPGT	3	Homo sapiens, Rattus norvegicus, Canis lupus familiaris
T100	PQPYPILPPGT	1	Mus musculus
T105	TLPPGTGRRIH	3	Homo sapiens, Rattus norvegicus, Canis lupus familiaris
T105	ILPPGTGRRIH	1	Mus musculus
T202	DLERLTQERIA	1	Homo sapiens
T202	DIQRLSQEHLE	1	Mus musculus
T202	DIQRLTQEHLE	1	Rattus norvegicus
T202	DLERLAQEHIE	1	Canis lupus familiaris
V87	RVVLPVWLNFD	2	Homo sapiens, Canis lupus familiaris
V87	RVVLPLWLNFD	2	Mus musculus, Rattus norvegicus
W117	YRGHLWLFRDA	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
W88	VVLPVWLNFDG	2	Homo sapiens, Canis lupus familiaris
W88	VVLPLWLNFDG	2	Mus musculus, Rattus norvegicus
Y112	RRIHSYRGHLW	4	Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupus familiaris
Y98	GEPQPYPTLPP	3	Homo sapiens, Rattus norvegicus, Canis lupus familiaris
Y98	GEPQPYPILPP	1	Mus musculus